| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D L Russell-Jones, A J Weissberge. The role of growth hormone in the regulation of body composition in the adult. Growth regulation. vol 6. issue 4. 1997-03-19. PMID:8971554. |
thus, adult gh deficiency, like acromegaly, has become widely accepted as a distinct clinical entity warranting treatment. |
1997-03-19 |
2023-08-12 |
human |
| C Invitti, L Fatti, M G Camboni, L Porcu, L Danesi, G Delitala, F Cavagnin. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients. Journal of endocrinological investigation. vol 19. issue 8. 1997-03-11. PMID:8905479. |
eight patients with clinically active acromegaly were treated for three months with octreotide nasal powder which was administered at the initial dosage of 0.125 mg tid, doubling the dosage up to 2 mg tid in order to obtain a mean gh value below 5 micrograms/l during 8 daytime hours. |
1997-03-11 |
2023-08-12 |
Not clear |
| J L Stock, M R Warth, B T Teh, J A Coderre, J H Overdorf, G Baumann, R L Hintz, M L Hartman, B R Seizinger, C Larsson, N Aroni. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. The Journal of clinical endocrinology and metabolism. vol 82. issue 2. 1997-03-11. PMID:9024241. |
screening of 26 members revealed the possible diagnosis of php in 1 family member in generation ii and possible early acromegaly in 2 members of generation iii with elevated serum concentrations of insulin-like growth factor i and insulin-like growth factor-binding protein-3 but normal patterns of pulsatile gh release. |
1997-03-11 |
2023-08-12 |
Not clear |
| J L Stock, M R Warth, B T Teh, J A Coderre, J H Overdorf, G Baumann, R L Hintz, M L Hartman, B R Seizinger, C Larsson, N Aroni. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. The Journal of clinical endocrinology and metabolism. vol 82. issue 2. 1997-03-11. PMID:9024241. |
in addition, further study of the earliest changes in patterns of pulsatile gh release in familial acromegaly may allow more insight into the pathogenesis and natural history of this disease. |
1997-03-11 |
2023-08-12 |
Not clear |
| C A Jaffe, R DeMott-Friberg, L A Frohman, A L Barka. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. The Journal of clinical endocrinology and metabolism. vol 82. issue 2. 1997-03-11. PMID:9024267. |
boluses of either ghrh-ant or saline on 24-h gh profiles in a patient with acromegaly due to a metastatic ghrh-secreting carcinoid tumor. |
1997-03-11 |
2023-08-12 |
human |
| C A Jaffe, R DeMott-Friberg, L A Frohman, A L Barka. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. The Journal of clinical endocrinology and metabolism. vol 82. issue 2. 1997-03-11. PMID:9024267. |
these data support the hypothesis that gh hypersecretion in the ectopic ghrh syndrome requires ghrh receptor occupancy and validates the use of ghrh-ant to probe the potential involvement of endogenous ghrh in patients with acromegaly due to pituitary somatotropinoma. |
1997-03-11 |
2023-08-12 |
human |
| C L Boguszewski, L Hynsjö, G Johannsson, B A Bengtsson, L M Carlsso. 22-kD growth hormone exclusion assay: a new approach to measurement of non-22-kD growth hormone isoforms in human blood. European journal of endocrinology. vol 135. issue 5. 1997-02-04. PMID:8980160. |
it is possible that increased amounts of non-22 k gh isoforms in the circulation contribute to the growth failure observed in some short children and may be involved in the pathophysiology of acromegaly and other unrelated diseases. |
1997-02-04 |
2023-08-12 |
human |
| F Marín, A M Picó, J G Martínez, J R Domínguez, R Alfayete, F Sogor. [Heart disease in acromegaly. Study of 27 patients]. Medicina clinica. vol 107. issue 9. 1997-01-03. PMID:8984234. |
the aim of this study was to evaluate the most relevant clinic, echocardiographic and holter recording findings in acromegaly and its correlation with the growth hormone (gh) levels and duration of the disease. |
1997-01-03 |
2023-08-12 |
Not clear |
| R Sheaves, P Jenkins, P Blackburn, A H Huneidi, F Afshar, S Medbak, A B Grossman, G M Besser, J A Was. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical endocrinology. vol 45. issue 4. 1997-01-02. PMID:8959078. |
previous studies of surgical treatment for acromegaly have used varied criteria for 'cure', but elevated gh levels are considered to be associated with continuing disease activity. |
1997-01-02 |
2023-08-12 |
Not clear |
| R Sheaves, P Jenkins, P Blackburn, A H Huneidi, F Afshar, S Medbak, A B Grossman, G M Besser, J A Was. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical endocrinology. vol 45. issue 4. 1997-01-02. PMID:8959078. |
we wished to analyse the results of transsphenoidal pituitary surgery for acromegaly and assess the longer-term outcome for patients not offered further treatment when post-operative levels of gh < 5 mu/l were achieved. |
1997-01-02 |
2023-08-12 |
Not clear |
| M al-Maskari, J Gebbie, P Kendall-Taylo. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical endocrinology. vol 45. issue 4. 1997-01-02. PMID:8959079. |
previous studies have shown that somatostatin analogues such as octreotide and lanreotide are effective in suppressing gh and igf-i levels in acromegaly, but the mode of administration and the frequency of injections were inconvenient for the patients. |
1997-01-02 |
2023-08-12 |
Not clear |
| M Louwerens, W W de Herder, P T Postema, H L Tanghe, S W Lambert. Pituitary insufficiency and regression of acromegaly caused by pituitary apoplexy following cerebral angiography. European journal of endocrinology. vol 134. issue 6. 1996-12-12. PMID:8766945. |
we present a patient with active acromegaly due to a growth hormone (gh)-secreting pituitary macroadenoma, who developed anterior and posterior pituitary insufficiency following cerebral angiography. |
1996-12-12 |
2023-08-12 |
Not clear |
| K Prank, M Kloppstech, S J Nowlan, T J Sejnowski, G Braban. Self-organized segmentation of time series: separating growth hormone secretion in acromegaly from normal controls. Biophysical journal. vol 70. issue 6. 1996-12-10. PMID:8744293. |
the pulsatile pattern of growth hormone (gh) secretion was assessed by sampling blood every 10 min over 24 h in healthy subjects (n = 10) under normal food intake and under fasting conditions (n = 6) and in patients with a gh-producing tumor (acromegaly, n = 6), before and after treatment with the somatostatin analog octreotide. |
1996-12-10 |
2023-08-12 |
human |
| S Melme. Acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769381. |
subcellular mechanisms support the notion of an intrinsic pituitary defect in acromegaly, with elevated growth hormone (gh) and insulin-like growth factor-1 (igf-1) levels that affect the cardiovascular and respiratory system, as well as neoplastic cell proliferative activity. |
1996-12-10 |
2023-08-12 |
Not clear |
| G Lombardi, A Colao, D Ferone, P Marzullo, M L Landi, S Longobardi, E Iervolino, A Cuocolo, S Fazio, B Merola, L Sacc. Cardiovascular aspects in acromegaly: effects of treatment. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769383. |
heart disease in acromegaly appears to be secondary to high circulating gh levels. |
1996-12-10 |
2023-08-12 |
Not clear |
| M C Sheppard, P M Stewar. Treatment options for acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769385. |
treatment options for acromegaly include surgical removal of the adenoma, radiotherapy, or pharmacological reduction of growth hormone (gh) levels by dopamine agonists or somatostatin analogs. |
1996-12-10 |
2023-08-12 |
human |
| M C Sheppard, P M Stewar. Treatment options for acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769385. |
we report on eight patients with a biochemical diagnosis of acromegaly (failure of suppression of gh levels to < 2.5 micrograms/l following a glucose tolerance test [gtt]). |
1996-12-10 |
2023-08-12 |
human |
| R Fahlbusch, J Honegger, M Buchfelde. Acromegaly--the place of the neurosurgeon. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769386. |
over 12 years, we performed 498 operations for growth hormone (gh)-secreting pituitary adenomas (489 in acromegaly and nine for gigantism), with 479 by the trans-sphenoidal and 19 by the transcranial route. |
1996-12-10 |
2023-08-12 |
Not clear |
| G Toli. The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769400. |
acromegaly mainly associated with the presence of a growth hormone (gh)-secreting pituitary tumor causes considerable morbidity and carries a risk of premature mortality. |
1996-12-10 |
2023-08-12 |
Not clear |
| T P Ip, F L Chan, A W Kung, K S La. Giant growth-hormone secreting pituitary tumour with extracranial extension. Australasian radiology. vol 40. issue 1. 1996-12-10. PMID:8838899. |
serum growth hormone (gh) was 52.6 mu/l basally and remained elevated after oral glucose, confirming the diagnosis of acromegaly. |
1996-12-10 |
2023-08-12 |
Not clear |